180 related articles for article (PubMed ID: 28267056)
21. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
22. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
23. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
24. The role of MRI in active surveillance for men with localized prostate cancer.
Recabal P; Ehdaie B
Curr Opin Urol; 2015 Nov; 25(6):504-9. PubMed ID: 26372037
[TBL] [Abstract][Full Text] [Related]
25. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
[TBL] [Abstract][Full Text] [Related]
26. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
27. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
28. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
29. Active surveillance in intermediate-risk prostate cancer.
Klotz L
BJU Int; 2020 Mar; 125(3):346-354. PubMed ID: 31647166
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
31. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
32. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
33. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
Tay KJ; Mendez M; Moul JW; Polascik TJ
Curr Opin Urol; 2015 May; 25(3):185-90. PubMed ID: 25768694
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
35. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital.
Osterberg EC; Palmer NRA; Harris CR; Murphy GP; Blaschko SD; Chu C; Allen IE; Cooperberg MR; Carroll PR; Breyer BN
Urol Oncol; 2017 Nov; 35(11):663.e9-663.e14. PubMed ID: 28826701
[TBL] [Abstract][Full Text] [Related]
37. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review.
Schoots IG; Petrides N; Giganti F; Bokhorst LP; Rannikko A; Klotz L; Villers A; Hugosson J; Moore CM
Eur Urol; 2015 Apr; 67(4):627-36. PubMed ID: 25511988
[TBL] [Abstract][Full Text] [Related]
38. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
Kattan MW; Eastham JA; Wheeler TM; Maru N; Scardino PT; Erbersdobler A; Graefen M; Huland H; Koh H; Shariat S; Slawin KM; Ohori M
J Urol; 2003 Nov; 170(5):1792-7. PubMed ID: 14532778
[TBL] [Abstract][Full Text] [Related]
39. How accurately can MRI detect indolent disease?
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2014 May; 24(3):264-9. PubMed ID: 24625426
[TBL] [Abstract][Full Text] [Related]
40. Active surveillance for favorable-risk prostate cancer: who, how and why?
Klotz L
Nat Clin Pract Oncol; 2007 Dec; 4(12):692-8. PubMed ID: 18037873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
